Scholar Rock Q3 2026 Earnings Date & Estimates

Scholar Rock (NASDAQ:SRRK) (NASDAQ: SRRK) is a clinical-stage biopharmaceutical company focused on developing medicines that selectively target the activation of growth factors. The company’s approach is designed to modulate biologic pathways in specific tissues while potentially limiting effects elsewhere in the body.

Scholar Rock’s lead product candidate is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin, a protein that negatively regulates muscle growth. The company is developing apitegromab for spinal muscular atrophy (SMA), a genetic neuromuscular disorder, and has evaluated the therapy in clinical studies involving patients with the disease. Its research has also included other growth-factor pathways and potential treatments for conditions involving muscle and tissue function.

Founded in 2012 and headquartered in Cambridge, Massachusetts, Scholar Rock conducts research and clinical development activities through collaborations and studies involving patients and medical centers in the United States and other countries. The company’s programs remain focused on advancing targeted biologic therapies rather than marketing a broad portfolio of commercial products. Jay Backstrom serves as president and chief executive officer.